# The International Immunotherapy Society for Fungal Diseases

**Authors:** Arturo Casadevall, Dimitrios P. Kontoyiannis, Frank L. van de Veerdonk

PMC · DOI: 10.1128/aac.01774-25 · Antimicrobial Agents and Chemotherapy · 2026-02-04

## TL;DR

This paper introduces a new society focused on developing immune therapies to improve outcomes for fungal disease patients.

## Contribution

The novel contribution is the establishment of the International Immunotherapy Society for Fungal Diseases.

## Key findings

- Current antifungal treatments have high morbidity and mortality rates.
- Immune therapy is proposed as a potential improvement for treatment outcomes.

## Abstract

The treatment of invasive fungal diseases is unsatisfactory because of high morbidity and mortality despite antifungal therapy. These patients are often immunocompromised, and improvements in treatment outcome are likely to require immune therapy. To promote immune therapies against fungal diseases, the International Immunotherapy Society for Fungal Diseases was organized.

## Full-text entities

- **Diseases:** Fungal Diseases (MESH:D009181)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12959142/full.md

## References

10 references — full list in the complete paper: https://tomesphere.com/paper/PMC12959142/full.md

---
Source: https://tomesphere.com/paper/PMC12959142